Thursday, April 01, 2010
Canadian Health Reference Guide - Saskatchewan Government and Health System Partners Release Plan to Improve Surgical Care
Note: no specific mention of ovarian cancer
Curis to Present at the 17th Annual Future Leaders in the Biotech Industry Conference - Hedgehog Pathway inhibitor GDC-0449 (financial news)
"Dan Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor. GDC-0449 is currently being developed in three Phase II clinical trials by Curis' collaborator Genentech, including in a pivotal Phase II trial in advanced basal cell carcinoma and Phase II trials in metastatic colorectal cancer and advanced ovarian cancer. Mr. Passeri will also discuss CUDC-101, Debio 0932 and Curis' other targeted cancer programs, in addition to other corporate activities.
There will be a corresponding webcast of the presentation, which can be accessed by visiting:
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com."
Best Evidence Interview: Use of Some SSRIs With Tamoxifen Increases Mortality in Breast Cancer Patients: A Best Evidence Interview With Catherine Kelly, MD
Note: included in interview is discussion of U.S./Canadian/Global research on this subject matter (reminder: Medscape articles are freely accessible with registration)
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary
Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer.